Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Apr 29, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a traditional Chinese medicine treatment called Fuzheng Yangxin prescription on patients recovering from coronary artery bypass grafting (CABG). CABG is a surgery that helps improve blood flow to the heart in people with serious heart problems. The trial is looking for patients who have undergone this surgery and are experiencing a condition known as Qi-Yin deficiency, which can cause fatigue and weakness. The goal of the study is to see if this herbal treatment can help these patients recover more quickly and safely after their surgery.

To participate in this trial, patients should be at least 18 years old and have recently had CABG surgery with symptoms of Qi-Yin deficiency. However, those with certain conditions, such as severe infections or significant liver and kidney problems, will not be eligible. If you join the study, you can expect to receive the Fuzheng Yangxin treatment along with standard care, and doctors will monitor your progress. This study aims to improve recovery methods after heart surgery by combining traditional Chinese medicine with standard treatments, potentially leading to better health outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who received coronary artery bypass surgery with syndrome differentiation of Qi-Yin deficiency after operation
• Exclusion Criteria:
• • ① Patients allergic to Fuzheng Yangxin Fang granules
• • Patients with postoperative cold and fever ③ Patients with severe postoperative hepatic and renal insufficiency ④ Other circumstances: Concurrent valvular surgery or other cardiac surgery, end-stage malignant tumor, uncontrolled infection, bleeding, progressive degenerative systemic disease, severe brain injury, multiple organ failure, other vital organ dysfunction such as severe liver impairment, severe heart failure or cardiogenic shock, inability to tolerate surgery, etc.